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Abstract
A recombinant heavy chain fragment C of botulinum neurotoxin serotype F (BoNTF(Hc)) has been expressed inPichia pastoris for
use as an antigen in a proposed human vaccine.P. pastoris cells were grown using glycerol batch, glycerol fed-batch, andmethanol fed-
batch methods to achieve high cell densities. The total cellular protein recovered after homogenization was 72mg/g of cell paste.
BoNTF(Hc) was purified from solublePichia cell lysate employing ion-exchange chromatographic (IEC) and hydrophobic interaction
chromatographic (HIC) methods developed at the bench scale using 10–100mL columns. The process was performed at the pilot scale
using 1–4L columns for evaluation of scale up. The purification process resulted in greater than 98% pure product consisting of at least
three forms of BoNTF(Hc) based on mass spectrometry and yielded up to 205mg/kg cells at the bench scale and 170mg/kg cells at the
pilot scale. Full-length BoNTF(Hc) is present based on mass spectrometry and SDS–PAGE, however is postulated to be N-terminally
blocked by acetylation. N-terminal sequencing showed that two of the three forms are missing the first 11 (80%) and 14 (20%) amino
acids of the N-terminus from the full-length form. The ratios of the two clipped forms were consistent from the bench to pilot scales.
Purified BoNTF(Hc) at the pilot scale was found to sufficiently protect mice against a high dose of BoNTF neurotoxin.
 2003 Elsevier Inc. All rights reserved.
There are seven serologically distinct forms (A–G) of
botulinum neurotoxins (BoNT)1 produced by Clostrid-
ium botulinum, each of which are the most toxic sub-
stances known to man [1]. Exposure to these agents
results in the disease botulism, which leads to fatal pa-
ralysis of respiratory muscles [2]. BoNT act on nerve cells
by inhibiting their release of the neurotransmitter ace-
tylcholine at neuromuscular junctions, thus preventing
muscle activation, leading to flaccid paralysis [3,5].
Active BoNT are produced by post-translational
modification of a 150-kDa precursor, resulting in a di-
chain consisting of a 100-kDa heavy chain and a 50 kDa
light chain connected by a disulfide bond [5,6]. The C-
terminus of the heavy chain (Hc) participates in the
*Corresponding author. Fax: 1-402-472-4985.
E-mail address: mmeagher1@unl.edu (M.M. Meagher).
1 Abbreviations used: BCA, bicinchoninic acid; BoNT, botulinum neurotoxin; BoNTF(Hc), botulinum neurotoxin serotype F, heavy chain C-
terminal fragment; BMGY, buffered minimal glycerol complex medium; BSA, bovine serum albumin; BSM, basal salts media; CHAPS, 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate; CV, column volume; DO, dissolved oxygen; EDTA, ethylenediaminetetraacetic acid,
disodium; ELISA, enzyme-linked immunosorbent assay; FF, fast flow; Hc, heavy chain C-terminal fragment; HIC, hydrophobic interaction
chromatography; HPLC, high performance liquid chromatography; IEC, ion-exchange chromatography; kDa, kilodalton; MW, molecular weight;
PEI, polyethyleneimine; PTM1, Pichia trace minerals 1; PVDF, polyvinylidene difluoride; Q, quaternary amine; SDS–PAGE, sodium dodecyl sulfate–
polyacrylamide gel electrophoresis; SP, sulfopropyl; WCW, wet cell weight.
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binding to specific receptors on cholinergic nerve cells
[7–12]. The N-terminal portion of the heavy chain
functions in translocation of the light chain of the
neurotoxin across the endosomal membrane [13–16].
The light chain, a zinc-endopeptidase [4,17–19], then
proteolytically cleaves key synaptic vesicle proteins,
which are required for neurotransmitter release [4,17–
20]. For nerve intoxication to completely occur, all
portions of the BoNT must be present. The Hc frag-
ments of BoNT A, B, C, E, and F were shown to be non-
toxic, antigenic [21], and capable of eliciting a protective
immunity in animals challenged with homologous
BoNT [22,23]. Therefore, these Hc fragments are being
developed as vaccine candidates for prevention of bot-
ulism [24–29].
A fermentation protocol utilizing glycerol batch,
glycerol fed-batch, and methanol fed-batch phases al-
lowed high cell densities to be reached. The induction
time was kept short (10 h) to optimize BoNTF(Hc)
production while minimizing the proteolytic degrada-
tion. Initial runs performed at the bench scale resulted in
much lower product yields than expected, which led us
to optimize the cell breakage step. A total of three
bench-scale runs were performed using cells generated
from either a 60 or 5L fermentation. Two pilot-scale
purification runs were performed using cells generated
from the same 60L fermentation to determine the ability
of this method to be scaled-up. For purification pro-
cesses, bench scale refers to purifications performed us-
ing columns less than 150mL, while pilot scale refers
to processing with columns on the > 0:5L scale (see
Materials and methods for actual column volumes).
Materials and methods
Five and 60L fermentation
A recombinant strain of Pichia pastoris (GS115)
transformed with pHIL-D4 plasmid containing a syn-
thetic gene encoding the putative heavy chain fragment
of botulinum serotype F (24) was used as seed culture
for all fermentations. A 1-L baffled shake flask con-
taining 150mL BMGY (buffered minimal glycerol
complex medium, Pichia Expression Kit, Invitrogen,
USA) was inoculated with 1mL of frozen strain stock
and incubated at 30 C, 200 rpm until an OD600 (optical
density at 600 nm) between 4 and 8 was reached. The
entire 150mL was employed as an inoculum for a 5-L
fermentor (Bioflo 3000, New Brunswick Scientific, USA)
containing 3L of BSM plus 0.435% v/v PTM1. BSM
consists of (per liter) 26.7mL of 85% H3PO4, 0.93 g
CaSO4, 18.2 g K2SO4, 14.9 g MgSO4  7H2O, 4.13 g
KOH, and 40.0 g glycerol; and PTM1 consists of (per
liter) 6.0 g CuSO4  5H2O, 0.08 g NaI, 3.0 g MnSO4 
H2O, 0.2 g Na2MoO4  2H2O, 0.02 g H3BO3, 0.5 g
CoCl2, 20.0 g ZnCl2, 65.0 g FeSO4  7H2O, 0.2 g biotin,
and 5.0mL H2SO4. Prior to inoculation, the pH was
adjusted to 5.0 with concentrated ammonium hydrox-
ide. The fermentation was controlled at pH 5.0, tem-
perature 30 C and dissolved oxygen (D.O.) >20% of
saturation. When the fermentation reached a density of
30–50 g/L wet cell weight (WCW), the culture was
transferred to a 80-L fermentor (MPP 80, New Bruns-
wick Scientific) containing 40L of BSM plus 0.435%
PTM1. When glycerol was exhausted, which was indi-
cated by a D.O. spike, a glycerol feed was initiated and
lasted for 4 h. The feed rate has the following profile:
first hour, 20 g/h/L (g 50% w/v glycerol containing 1.2%
v/v PTM1/h/L initial medium); second–fourth hour, feed
rate decreased linearly from 20 g/h/l to 0. At the end of
first hour, methanol was added to the fermentation
vessel to achieve a concentration of 1.5 g/L. At the end
of the third hour, a methanol feed was initiated and the
feed rate was programmed to increase linearly using the
following profile: 0 h, 4 g/h/L (g 100% methanol con-
taining 1.2% v/v PTM1/h/L initial medium); 2.4 h, 6 g/h/
L; 3.8 h, 7 g/h/L; and 8.5 h, 9 g/h/L. The methanol feed
rate was adjusted using the dissolved oxygen spike
method [30]. The total induction time on methanol was
10.5 h. The final cell density was about 170 g/L wet
weight.
5L cell harvest and disruption
Cells harvested from a 5L fermentation were spun at
8000g at 4 C for 20min using a Beckman J2-21 Cen-
trifuge (Palo Alto, CA). Cell paste was then either
frozen at )20 C or processed immediately. Cell paste
was resuspended in 25 mM sodium acetate + 5mM
EDTA, pH 5.0, to either 10 or 26% (w/v) solids. Cells
were then homogenized using a Microfluidizer M-
110EH (Microfluidics, Newton, CA) set at 21,000 psi. A
total of 3–5 passes were performed to obtain at least
75% cell disruption. The homogenate was then brought
to 0.25% Polyethyleneimine (PEI) using a 5% (w/v)
stock solution at pH 7.0. This was allowed to mix for 30
min at 4 C. The resulting mixture was processed by
centrifugation at 10,000g for 20min at 4 C. The su-
pernatant was then decanted, passed through a 0.2 lm
cellulose acetate filter, and saved for further immediate
processing.
Bench scale purification
All bench scale chromatographic separations were
performed on a BioCad Workstation (PE Biosystems,
Foster City, CA) at room temperature, with the load
material on ice. Supernatant was passed through a
0.2 lm polyethersulfone (PES) filter and was loaded
onto a 100mL SP Sepharose FF column (2.6 19 cm)
(Amersham Pharmacia) equilibrated with 5 column
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volumes (CV) of 25mM sodium acetate + 1mM EDTA,
pH 5.0. The linear velocity used for this column was
250 cm/h. The column was washed with 5CV equili-
bration buffer, followed by a wash step with 25mM
sodium phosphate + 1mM EDTA, pH 6.8. The product
was eluted using a 20CV linear gradient from 0 to 1M
sodium chloride in 25mM sodium phosphate + 1mM
EDTA, pH 6.8. The product starts to elute at a con-
ductivity of 20mS/cm.
The SP Sepharose product was adjusted to 1M am-
monium sulfate using a 3.5M ammonium sulfate stock.
The adjusted solution was allowed to mix at room
temperature for at least 30min and then filtered through
a 0.2 lm filter. The filtered material was then loaded
onto a 32mL butyl Sepharose 4 FF column
(1.6 16 cm) (Amersham Pharmacia) equilibrated with
5CV 1M ammonium sulfate + 25mM sodium phos-
phate + 1mM EDTA, pH 6.8. The linear velocity used
for this column was 300 cm/h. The column was washed
with 5CV of equilibration buffer and the product was
eluted using a 10CV linear gradient from 1 to 0M
ammonium sulfate in sodium phosphate + 1mM EDTA,
pH 6.8. BoNTF(Hc) elutes as the second major peak at
approximately 60mS/cm conductivity.
The butyl Sepharose product was dialyzed vs. 20
volumes of 25mM sodium acetate + 1mM EDTA, pH
5.0, using 10 kDa Slide-A-Lyzer cassettes (Pierce,
Rockford, Il) at 4 C. The dialyzed product was loaded
onto a 13-mL ToyoPearl SP 650M column (1.0
17 cm) (TosoHaas, Montgomeryville, PA) equilibrated
with 5CV of 25mM sodium acetate + 1mM EDTA, pH
5.0. The linear velocity used for this column was
300 cm/h. After loading, the column was washed with
5CV of equilibration buffer. BoNTF(Hc) was eluted
from the column using a 20CV linear gradient
from equilibration buffer to 100mM sodium phos-
phate + 1mM EDTA, pH 7.0. The product elutes at the
end of the gradient as the second major peak at
approximately 13mS/cm conductivity. Final product
was then stored at )20 C.
60L cell harvest and disruption
Fermentation broth was diluted to 10% solids with
distilled water prior to centrifugation and harvested
using a Westfalia CSA8 disk-stack separator (Oelde,
Germany). The resulting cell paste was either frozen at
)20 C or processed immediately. The cell paste was
brought to 21–26% (w/v) solids using 25mM sodium
acetate + 5mM EDTA, pH 5.0. Cells were disrupted
using an APV Gaulin 30-CD Homogenizer (Everett,
MA) at 16,000 psi maintained at 10 C. Harvested cells
were exposed to 3–5 passes through the homogenizer
and cooled to 10 C prior to the next pass using a
chilled heat exchanger. The resulting homogenate was
brought to 0.25% PEI using a 5% (w/v) stock and
allowed to mix for 30min at 10 C. The resulting
mixture was separated using the Westfalia described
above. The supernatant was sterile-filtered using 1000
0.2 lm Fluorodyne II filters (Pall, East Hills, NY) and
transferred to the purification pilot plant for further
processing.
Pilot scale purification
All chromatographic separations were performed on
a NC-SRT pilot-scale chromatography skid. For each
chromatographic step, conditions were the same as the
bench-scale work, i.e., identical linear velocities, equili-
bration, washing, and elution methods. The SP Sepha-
rose FF step was performed using a 4L (20 13 cm)
BPG 200/500 column (Amersham Pharmacia Biotech,
Piscataway, NJ). The butyl Sepharose 4 FF step was
performed on a 1.3 L (10 16 cm) BPG 100/500 column
(Amersham Pharmacia), while the final ToyoPearl SP
650M step was performed using a 526mL (6.1 18 cm)
Vantage 60A column (Millipore, Bedford, MA). The SP
Sepharose product was brought to 1M ammonium
sulfate by addition of granular ammonium sulfate. The
diafiltration step was performed using a 3 sq. ft. 10 kDa
spiral wound membrane (Millipore). The material was
diafiltered with 3 volumes of 25mM sodium ace-
tate + 1mM EDTA, pH 5.0, at which time the retentate
pH was 5.0 and the conductivity 4.7mS at 10 C. The
retentate was then concentrated approximately 2-fold
and filtered through a 0.45 lm CA filter prior to loading
onto the final column. Final product of the ToyoPearl
SP 650M column was sterile-filtered through a 0.2 lm
Supor capsule filter (Pall, East Hills, NY) and stored at
)20 C.
Protein analysis
Total protein concentrations were determined using
the BCA (Pierce) Standard Assay, using BSA as a
standard. Purity was determined by SDS–PAGE using
4–20% polyacrylamide gels (Novex, San Diego, CA)
stained with Coomassie blue or silver stain. Western
blot analysis was performed using polyclonal Protein
G-Sepharose-purified horse anti-BoNTF antibody in-
cubated at 1 lg/mL for 1 h. The secondary antibody
was a horseradish peroxidase labeled affinity-purified
goat anti-horse IgG (Kirkegaard & Perry Laboratories,
Gainsburg, MD) incubated at 1 lg/mL for 1 h. SDS–
PAGE-separated proteins were transferred to PVDF
membranes (BioRad, Hercules, CA) at 100V for 1 h,
blocked with 5% non-fat dried milk for 1 h, and washed
with 0.05% Tween 20 in phosphate-buffered saline
(PBS) prior to treatment with antibodies. Blots were
then visualized by Chemiluminescence using the ELC
plus Detection Kit (Amersham Pharmacia Biotech,
Piscataway, NJ). N-terminal sequencing was performed
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by the University of Nebraska-Medical Center Protein
Core Facility using automated Edman degradation
performed on a Procise model 491-HT amino acid se-
quencer (PE Biosystems, Foster City, CA). Liquid
chromatography quadrupole time-of-flight mass spec-
trometry (LC Q-TOF MS) experiments were performed
at the University of Nebraska Center for Mass Spec-
trometry using a Micromass Q-TOF mass spectrometer
coupled to a Shimadzu HPLC (Shimadzu, Kyoto, Ja-
pan) using a C4 reverse phase Micro trap column
(Michrom Bioresources, Auburn, CA). For LC sepa-
ration, buffer A consisted of 0.1% formic acid in water
and buffer B consisted of 0.1% formic acid in acetoni-
trile. After loading, the column was washed for 8min at
10% buffer B. The BoNTF(Hc) was eluted from the
column using a 5-min gradient from 10 to 70% buffer
B. Elution was monitored by total ion current and base
ion current detection using the MassLynxTM software
(Waters, Milford, MA). Raw mass spectroscopy data
were deconvoluted to generate parent ions mass
spectra.
Mouse inoculations and BoNTF toxin challenge
The efficacy of purified BoNTF(Hc) was determined
by toxin challenge studies on mice. Groups of 10 female
mice (CD1, ICR mice (Charles Rivers, NC) weighing
16–22 g on receipt) were intramuscularly vaccinated
(into the caudal muscle of the right rear limb) with two
(2) or three (3) doses of either 0.04, 0.2, 1 or 5 lg
BoNTF(Hc). Vaccine was diluted in 0.2% (v/v) Alhy-
drogel (HCI Biosector, Frederikssund, Denmark) con-
taining 100mM sodium chloride and injections were
administered at 4 week intervals (100 lL/injection). Mice
were challenged 14 days post-vaccination with 1000
mouse LD50 with BoNTF toxin complex (Langeland
strain) where the 1000 mouse LD50 is 1000 times the
dose (by volume) necessary to kill 50% of mice in a
group being challenged. Mice were observed daily and
deaths were recorded 5 days post challenge.
Results and discussion
Bench scale fermentation and purification
Seed cultures of a recombinant strain of GS115
P. pastoris containing the pHIL-D4 plasmid containing
a synthetic gene encoding the putative heavy chain
fragment of botulinum serotype F [24] were used as an
inoculum. Five-liter bench scale fermentations involved
standard methanol feed rates (see Materials and
methods), with up to a 10-h induction. This short
induction time was necessary to minimize the effect of
proteolytic cleavage, yet still reached sufficient levels of
expression.
Initial harvest processing resulted in a significantly
lower product yield than expected (54.35mg BoNTF
(Hc)/kg cell) compared to published results [24]. It was
postulated that cell breakage at a higher percent solids
would result in a much higher amount of cell lysis (the
term ‘‘solids’’ is defined as the mass of cell paste present
per volume of solution). An experiment was performed
to test the amount of total protein released by homog-
enization at different percent solids (see Fig. 1). Cells
were broken using a bead beater set up. This breaking
system consists of cell pellet mixed to the appropriate
percent solids with breaking buffer and an equal volume
of Zirconia beads placed in a blending apparatus. Cells
were broken by six cycles of 1min blending and 5min
cooling on ice. These results show a 6-fold increase in
the amount of protein released by increasing the percent
solids from 10 to 26%. These results were also confirmed
during breakage using the Microfluidizer described in
Materials and methods. We also found that for opti-
mum release of protein during disruption, harvested cell
paste should be processed immediately and not frozen.
It is postulated that extended frozen storage of cells
causes them to be more difficult to disrupt [28]. There-
fore, subsequent cell disruptions were performed at 26%
solids and were conducted immediately after harvesting.
Harvested material was purified at the bench scale
using ion exchange and hydrophobic interaction chro-
matography techniques. SP Sepharose FF resin was used
to capture the target product due to its direct scalability
and sufficient binding capacity for BoNTF(Hc) antigen.
The maximum total protein loaded onto the SP Sepha-
rose FF column was 55.5mg/mL resin. At this load, less
than 3% of the product introduced to the column was
seen in the flow through. Material eluted from the cap-
ture column was further processed through a butyl
Sepharose FF. This resin was found to remove a ma-
jority of the smaller molecular weight Pichia proteins
present after capture. A maximum protein load of
4.8mg/mL resin was used for the butyl Sepharose 4 FF
Fig. 1. Effect of percent solids (w/v) on cell breakage. Cells harvested
from 5 and 60L fermentations were adjusted to the appropriate solids
(w/v), homogenized, and exposed to centrifugation. Resulting super-
natants were analyzed for total protein concentration using the
Bradford protein assay (BioRad) using BSA as the standard.
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column and Western blot analysis of the flow through
showed no signs of BoNTF(Hc) present. A ToyoPearl SP
650M resin was used as a polishing column to remove a
63 kDa contaminant as well as some smaller molecular
weight proteins. A total protein load of 2.7mg/mL resin
for this final column resulted in no BoNTF(Hc) detected
in load flow through. The entire purification process,
from harvesting to final sterile-filtering, was performed
in 20 h.
For an overall evaluation of this purification process,
a total of three purification processes were performed at
the bench scale. Results of these purification runs were
very similar in product yield, purity, and elution profiles.
Purification runs resulted in final product yields, ranging
from 155 to 205mg BoNTF(Hc)/kg cells (Table 1). A
typical purification resulted in at least 98% pure
BoNTF(Hc), which consisted of at least two forms of
the product based on SDS–PAGE (Fig. 2). Analysis by
N-terminal sequencing shows the prominent form (80%
of the total) of the product to be missing the first 11
amino acids ()11) and a second form (20% of the total)
missing the first 14 amino acids of the amino terminus
()14) (see Table 2). The ratio of product forms was
consistent for all purification processes performed at
both the bench and pilot scales. Results from these two
analytical methods are conflicting due to the fact that
SDS–PAGE shows the lower band ()14) to have the
greatest intensity of the two, while the )14 form is only
20% of the total by N-terminal sequencing.
To shed light on this inconsistency, liquid chroma-
tography-quadrupole time-of-flight mass spectrometry
analysis was performed. We postulated that the N-ter-
minus was acetylated which would block N-terminal
sequencing of this form and that the )11 and )14
were not being resolved by SDS–PAGE. Results of
the MS experiment shows three groups of species of
BoNTF(Hc) present; (1) 50,161 5.69Da, (2) 48,959
2.93Da, and (3) 48,533 9.20Da (see Fig. 3). The main
component of each peak group was used for data
analysis. Specie 1 is consistent with removal of the
Table 1
Bench scale purification of BoNTF(Hc)a
Step Volume
(mL)
[Protein]Total
(mg/mL)
Total
protein (mg)
Estimated
purityb (%)
BoNTF
(Hc)c (mg)
Step yield
(%)
Total yield
(%)
Lysate 820 13.26 10873 <0:5 54.4 (100) (100)
PEI-treatment 740 7.65 5661 <1 45.3 83 83
SP Sepharose FF 270 0.64 174 25 43.4 96 80
Adjusted SP Sepharose FF 380 0.42 161 26 41.9 97 77
Butyl Sepharose 4 FF 87 N.D. N.D. 87 N.D. N.D. N.D.
Dialyzed butyl Sepharose 4 FF 88 0.43 37.9 87 33.0 N.D. 61
ToyoPearl SP 650M 65 0.36 23.3 98 22.9 69 42
N.D., not determined.
a Purification is from 150 g cells wet weight.
b Estimated by visual inspection of SDS–PAGE.
cDetermined by multiplication of total protein and purity.
Fig. 2. (A) Silver stained SDS–PAGE and (B) chemiluminescent
Western blot analysis of purified BoNTF(Hc) from a typical bench-
scale purification (PDL-004). (A) Lane 1 is MW standards and lane 2 is
2.5 lg final product and (B) lane 1 is 50 ng final product.
Table 2
N-terminal sequence of purified BoNTF(Hc)
Sample N-Terminal sequence
Intact BoNTF(Hc) MSYTN DKILI LYFNK
LYKKI KDNSI
Bench scale PDL-004 YFNK LYKKI K 80% ()11)
K LYKKI XDNX 20% ()14)
PDL-005 YFNK LYKKI K 75% ()11)
K LYKKI KDN 25% ()14)
PDL-006 YFNK LYKKI K 76% ()11)
K LYKKI XDNX 24% ()14)
PDL-007 YFNK LYKKI K 80% ()11)
K LYKKI KDN 20% ()14)
Pilot scale PPP-006 YFNK LYKKI K 89% ()11)
K LYKKI KDN 11% ()14)
PPP-007 YFNK LYKKI K 77% ()11)
K LYXXI XDNS 23% ()14)
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N-terminal methionine and acetylation which has a
theoretical mass of 50,172.5Da (the theoretical full-
length BoNTF(Hc) mass is 50,261.5Da). Acetylation of
N-terminal serine has been documented in yeast [30].
Species 2 and 3 are consistent with the )11 and )14
forms of BoNTF(Hc), respectively. These mass spec-
trometry experiments are preliminary and require more
detailed experimentation to fully resolve this issue,
however we feel these data provide support for our hy-
pothesis of N-terminal acetylation of our product.
It was postulated that the two shortened BoNTF(Hc)
forms may be the result of proteolytic degradation
during fermentation/harvesting or incomplete cellular
processing. Fermentation was performed with a short-
ened methanol induction time of 3 h, in an attempt to
avoid prolonged exposure of product to protease activ-
ity and still produce sufficient amounts of full-length
BoNTF(Hc). Immediate purification of this fermenta-
tion resulted in a 2-fold reduction of product yield and
N-terminal sequence analysis showed both forms of the
clipped product similar to previous purifications.
Initial bench-scale processing showed minor higher
molecular weight contaminates present in the final
BoNTF(Hc) product. An attempt to remove these
Pichia proteins was performed using the zwitterionic
detergent, CHAPS as an additive in the initial column
buffers. We found that 0.25% CHAPS did not aid in
the removal of these proteins (data not shown). Also
unsuccessful was an attempt using a negative purifica-
tion step with Q Sepharose FF following the capture
step with CHAPS present in the buffers. BoNTF(Hc)
from this experiment did not show an increase in pu-
rity. We did find that these contaminants may be
avoided by making a very detailed cut in collection of
product eluting from the SP Sepharose FF column.
Such detail in fraction collecting is difficult to perform
at the pilot scale, and leads to lower product yields as
the elution of these contaminants and BoNTF(Hc)
overlap.
Pilot scale fermentation and purification
Two 60L fermentations and two pilot scale
purification runs were performed. These fermentations
resulted in final wet cell weights of 21.2–30.8% with final
volumes of 56 and 57L, respectively.
The initial pilot scale purification run was performed
using freshly harvested cells and resulted in 179mg
BoNTF(Hc)/kg cell. The product from the SP Sepha-
rose FF capture column was collected in bulk with
collection beginning as soon as the Abs280 began to
increase. Upon completion of this purification run, the
final product was found to contain two minor higher
molecular weight contaminants. These contaminants
were the result of the ‘‘broad’’ cut made during prod-
uct collection off the capture column. These contami-
nants co-elute significantly with BoNTF(Hc) and
proved difficult to remove during subsequent chroma-
tography steps.
A second pilot scale purification was performed using
frozen cells from the same fermentation run and gen-
erated a higher purity product (Fig. 4), however yielded
5-fold less BoNTF(Hc)/kg cell paste (Table 3). During
Fig. 3. Liquid chromatography quadrupole time-of-flight mass spectra
of purified BoNTF(Hc). Relative intensities of each peak group are
displayed along with normalized intensities for comparison. Raw mass
spectroscopy data were deconvoluted to generate parent ions mass
spectra. The main component of each peak group was used for data
analysis.
Fig. 4. (A) Coomassie blue-stained SDS–PAGE and (B) chemilumi-
nescent Western blot of purified BoNTF(Hc) from a pilot-scale puri-
fication (PPP-007). (A) Lane 1 is 5lg final product and lane 2 is MW
standards. (B) Lane 1 is 50 ng final product.
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this second purification process, product collection be-
gan only at the apex of the elution peak off the capture
column. This was performed based on development
data, which showed the higher molecular weight con-
taminants co-eluting in the front half of the product
peak.
The entire purification process from harvesting to
final sterile-filtering took about 25 h, similar to the time
required for bench scale processing. Processing at the
pilot scale resulted in a similar product yield per kilo-
gram cell. The changes in processing relative to the
bench scale were in the type of equipment used to per-
form certain tasks, i.e., dialysis cassettes vs. diafiltration
systems. In order to remove cell debris and flocculated
nucleic acid from cellular homogenate, a disk-stacked
separator was used rather than conventional laboratory
centrifugation. This equipment was able to reduce the
harvest process time by one-half and resulted in the
same quality material seen at the bench scale.
To adjust the butyl Sepharose 4 FF product to
25mM sodium acetate + 1mM EDTA, pH 4.5, a dia-
filtration system was used with a jacketed stainless-steel
sample reservoir, chilled to 7 C. This step resulted in an
insignificant loss of product and took only 2 h to per-
form using a 10-kDa spiral-wound regenerated cellulose
membrane. During adjustment of the SP Sepharose FF
product to 1.0M ammonium sulfate, some precipitation
was seen initially, however, if added slowly in incre-
ments over a 1-h period with continuous mixing, this
was minimized. This phenomenon was more prominent
at the pilot scale, possibly due to an increased sample
temperature upon mixing. During adjustment at the
pilot scale, the sample was approximately 17 C, three
times the temperature this step was performed at for the
bench scale process, which may have caused the protein
to be less stable.
Mouse efficacy studies
To determine the efficacy of the purified BoNTF(Hc),
mouse challenge studies were performed using purified
pilot plant material using doses ranging from 0.04 to
5 lg/mouse. All mice were challenged ip with 1000
LD50 BoNTF toxin complex. A double inoculation of
5 lg dose protected nine of 10 mice, while with a
triple inoculation all 10 mice survived (Table 4). All
10 mice survived with two doses of 1 lg, whereas nine
of 10 mice were protected with three doses of the
same amount. When a low dose of 0.04 lg was used,
seven of 10 mice survived whether they received two
or three inoculations. None of the control mice sur-
vived (0/10). With a dose of 1 lg or greater, 95% (19/
20) of the mice were protected using either a double
or triple inoculation schedule. All 10 mice survived
when inoculated three times with 0.2 lg, while eight of
10 mice survived when inoculated two times, sug-
gesting that increased inoculations provide increased
protection.
Conclusion
The production and purification of recombinant
BoNTF(Hc) from P. pastoris using the process de-
scribed above has been scaled-up and can result in a
similar product purity at both the bench and pilot
scales. Fermentations achieved high cell densities and
reached optimum BoNTF(Hc) production after 10 h
induction. Purified BoNTF(Hc) at the pilot scale was
found to offer adequate protection in mouse challenge
studies. It was found that to achieve maximum
Table 3
Pilot scale purification of BoNTF(Hc)a
Step Volume
(L)
[Protein]Total
(mg/mL)
Total
protein (g)
Estimated
purityb (%)
BoNTF
(Hc)c (g)
Step Yield
(%)
Total yield
(%)
Lysate 15 15.21 228 <2 1.14 (100) (100)
PEI-Treatment 46 0.80 36.8 <3 0.92 81 81
SP Sepharose FF 15.5 0.11 1.7 25 0.43 47 38
Adjusted SP Sepharose FF 16.5 0.10 1.6 33 0.39 91 34
Buytl Sepharose 4 FF 3.5 0.10 0.4 80 0.28 72 25
Diafilterd butyl Sepharose 4 FF 2.5 0.07 0.2 80 0.13 47 12
ToyoPearl SP 650M 2.3 0.04 0.1 98 0.09 69 8
a Purification is from 2.87 kg cells wet weight.
b Estimated by visual inspection of SDS–PAGE.
cDetermined by multiplication of total protein and purity.
Table 4
Survival of mice after vaccination with purified BoNTF(Hc)
Inoculation dose (lg) Survival (alive/10 tested)
2 3
5 9 10
1 10 9
0.2 8 10
0.04 7 7
PBS 0 0
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BoNTF(Hc) yield, purification should be performed
immediately upon completion of the fermentation. The
purification process involves three chromatographic
steps, which is typical of methods used to purify non-
secreted products from Pichia, and results in three
product forms, an N-terminal acetylated form missing a
methionine residue and two clipped forms missing the
first 11 and 14 amino acids, respectively. The ratio of
clipped forms was found to be consistent regardless of
processing at the bench or pilot scales. This material
provided adequate protection of mice against 1000 LD50
BoNTF toxin complex (see Materials and methods)
when inoculated with three doses of 1 lg BoNTF(Hc)
over a 12-week period.
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